alendronate has been researched along with Osteoarthritis of Knee in 16 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This trial will give helpful and high-quality evidence regarding the potential therapeutic role of alendronate sodium vitamin D3, as compared to placebo, in the management of patients with knee OA regarding its role on cartilage loss, radiographic progression of OA, severity of OA, knee pain, quality of life, and inflammatory biomarkers." | 5.51 | Effect of alendronate sodium plus vitamin D ( Cai, DZ; Feng, B; Li, Y; Peng, HM; Qian, W; Wan, S; Weng, XS; Yang, Y; Yao, ZJ; Zhang, C; Zhao, C, 2022) |
| "Between 2006 and 2009, 17 consecutive patients (mean age 68 years) with clinical and radiographic signs of knee osteonecrosis were identified and given alendronate, 70 mg perorally, once a week for a minimum of 6 months." | 3.78 | Treatment of spontaneous osteonecrosis of the knee (SPONK) by a bisphosphonate. ( Geijer, M; Jureus, J; Lindstrand, A; Roberts, D; Tägil, M, 2012) |
| "Bisphosphonates inhibit bone resorption and may reduce this loss in BMD." | 2.80 | Effect of one-year post-operative alendronate treatment on periprosthetic bone after total knee arthroplasty. A seven-year randomised controlled trial of 26 patients. ( Jaroma, AV; Kröger, H; Soininvaara, TA, 2015) |
| "By reducing the bone resorption after implantation of a joint replacement, it should be possible to enhance the initial fixation of the implant." | 2.74 | Once-weekly oral medication with alendronate does not prevent migration of knee prostheses: A double-blind randomized RSA study. ( Aspenberg, P; Hansson, U; Ryd, L; Toksvig-Larsen, S, 2009) |
| "Loading induced cartilage pathology, osteophyte formation, and SCB changes; however, lower initial SCB mass and stiffness in B6 mice did not attenuate load-induced OA severity compared to FVB mice." | 1.46 | Role of subchondral bone properties and changes in development of load-induced osteoarthritis in mice. ( Adebayo, OO; Goldring, MB; Goldring, SR; Ko, FC; van der Meulen, MCH; Wan, PT; Wright, TM, 2017) |
| "Alendronate treatment reduced bony osteophyte development." | 1.36 | In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat. ( Doschak, MR; Jones, MD; Li, G; Maksymowych, WP; Tran, CW; Zernicke, RF, 2010) |
| "Alendronate use was also associated with a reduction in knee pain according to the WOMAC scores." | 1.32 | The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. ( Barrow, KD; Carbone, LD; Felson, D; Harris, F; Harris, TB; Kritchevsky, SB; Nevitt, MC; Peterfy, C; Visser, M; Wang, BW; Wildy, K, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Peng, HM | 1 |
| Weng, XS | 1 |
| Li, Y | 1 |
| Feng, B | 1 |
| Qian, W | 1 |
| Cai, DZ | 1 |
| Zhao, C | 1 |
| Yao, ZJ | 1 |
| Yang, Y | 1 |
| Zhang, C | 1 |
| Wan, S | 1 |
| Ballal, P | 1 |
| Sury, M | 1 |
| Lu, N | 1 |
| Duryea, J | 1 |
| Zhang, Y | 1 |
| Ratzlaff, C | 1 |
| Neogi, T | 1 |
| Adebayo, OO | 1 |
| Ko, FC | 1 |
| Wan, PT | 1 |
| Goldring, SR | 1 |
| Goldring, MB | 1 |
| Wright, TM | 1 |
| van der Meulen, MCH | 1 |
| Lee, JK | 1 |
| Choi, CH | 1 |
| Kang, CN | 1 |
| Mohan, G | 1 |
| Perilli, E | 1 |
| Parkinson, IH | 1 |
| Humphries, JM | 1 |
| Fazzalari, NL | 1 |
| Kuliwaba, JS | 1 |
| Jaroma, AV | 1 |
| Soininvaara, TA | 2 |
| Kröger, H | 1 |
| Khorasani, MS | 1 |
| Diko, S | 1 |
| Hsia, AW | 1 |
| Anderson, MJ | 1 |
| Genetos, DC | 1 |
| Haudenschild, DR | 1 |
| Christiansen, BA | 1 |
| Hansson, U | 1 |
| Toksvig-Larsen, S | 1 |
| Ryd, L | 1 |
| Aspenberg, P | 1 |
| Jones, MD | 1 |
| Tran, CW | 1 |
| Li, G | 1 |
| Maksymowych, WP | 1 |
| Zernicke, RF | 1 |
| Doschak, MR | 1 |
| Shirai, T | 1 |
| Kobayashi, M | 1 |
| Nishitani, K | 1 |
| Satake, T | 1 |
| Kuroki, H | 1 |
| Nakagawa, Y | 1 |
| Nakamura, T | 1 |
| Jureus, J | 1 |
| Lindstrand, A | 1 |
| Geijer, M | 1 |
| Roberts, D | 1 |
| Tägil, M | 1 |
| Jurvelin, JS | 1 |
| Miettinen, HJ | 1 |
| Suomalainen, OT | 1 |
| Alhava, EM | 1 |
| Kröger, PJ | 1 |
| Hayami, T | 1 |
| Pickarski, M | 1 |
| Wesolowski, GA | 1 |
| McLane, J | 1 |
| Bone, A | 1 |
| Destefano, J | 1 |
| Rodan, GA | 1 |
| Duong, LT | 1 |
| Carbone, LD | 1 |
| Nevitt, MC | 1 |
| Wildy, K | 1 |
| Barrow, KD | 1 |
| Harris, F | 1 |
| Felson, D | 1 |
| Peterfy, C | 1 |
| Visser, M | 1 |
| Harris, TB | 1 |
| Wang, BW | 1 |
| Kritchevsky, SB | 1 |
| Young-Min, SA | 1 |
| Herbert, L | 1 |
| Dick, M | 1 |
| Fordham, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Alendronate Sodium Vitamin D3 Tablets on Knee Joint Structure and Knee Osteoarthritis Pain: A Multi-center, Randomized, Double-blind, Controlled Study.[NCT04739592] | Phase 4 | 60 participants (Anticipated) | Interventional | 2021-07-07 | Recruiting | ||
| An Open-Label Phase 2 Study of Abaloparatide to Mitigate Distal Femoral Bone Loss Following Total Knee Arthroplasty[NCT04167163] | Phase 4 | 58 participants (Actual) | Interventional | 2020-01-10 | Active, not recruiting | ||
| A Randomized Placebo Controlled Trial Testing The Effect of Zoledronic Acid on Hip Osteoarthritis[NCT04303026] | Phase 3 | 70 participants (Anticipated) | Interventional | 2020-03-02 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for alendronate and Osteoarthritis of Knee
| Article | Year |
|---|---|
Effect of alendronate sodium plus vitamin D
Topics: Alendronate; Cholecalciferol; Double-Blind Method; Humans; Knee Joint; Multicenter Studies as Topic; | 2022 |
Effect of one-year post-operative alendronate treatment on periprosthetic bone after total knee arthroplasty. A seven-year randomised controlled trial of 26 patients.
Topics: Aged; Alendronate; Arthroplasty, Replacement, Knee; Bone Density; Bone Density Conservation Agents; | 2015 |
Once-weekly oral medication with alendronate does not prevent migration of knee prostheses: A double-blind randomized RSA study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Arthroplasty, Replacement, Knee; Bone De | 2009 |
Effect of alendronate on periprosthetic bone loss after total knee arthroplasty: a one-year, randomized, controlled trial of 19 patients.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthroplasty, Replacement, Knee; Bone Density; Bone Resor | 2002 |
12 other studies available for alendronate and Osteoarthritis of Knee
| Article | Year |
|---|---|
The relation of oral bisphosphonates to bone marrow lesion volume among women with osteoarthritis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Marrow; Diphosphonates; Female; Humans; Ib | 2020 |
Role of subchondral bone properties and changes in development of load-induced osteoarthritis in mice.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Cancellous Bo | 2017 |
Quantitative computed tomography assessment of bone mineral density after 2 years' oral bisphosphonate treatment in postmenopausal osteoarthritis patients who underwent total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Alendronate; Arthroplasty, Replacement, Knee; Bone Density; Bone Density Co | 2013 |
Pre-emptive, early, and delayed alendronate treatment in a rat model of knee osteoarthritis: effect on subchondral trabecular bone microarchitecture and cartilage degradation of the tibia, bone/cartilage turnover, and joint discomfort.
Topics: Alendronate; Animals; Arthritis, Experimental; Bone Density Conservation Agents; Cartilage Oligomeri | 2013 |
Effect of alendronate on post-traumatic osteoarthritis induced by anterior cruciate ligament rupture in mice.
Topics: Alendronate; Animals; Anterior Cruciate Ligament Injuries; Bone Density Conservation Agents; Bone Re | 2015 |
In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat.
Topics: Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Dis | 2010 |
Chondroprotective effect of alendronate in a rabbit model of osteoarthritis.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Cartilage, Articular; Drug Evaluation, Precl | 2011 |
Treatment of spontaneous osteonecrosis of the knee (SPONK) by a bisphosphonate.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Female; Humans; Knee Joint; Male; Middle Aged; | 2012 |
The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model.
Topics: Acid Phosphatase; Alendronate; Animals; Anterior Cruciate Ligament; Bone Remodeling; Calcinosis; Car | 2004 |
The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis.
Topics: Aged; Alendronate; Arthrography; Bone Resorption; Case-Control Studies; Cross-Sectional Studies; Est | 2004 |
Weekly alendronate-induced acute pseudogout.
Topics: Alendronate; Chondrocalcinosis; Female; Humans; Middle Aged; Osteoarthritis, Knee; Osteoporosis, Pos | 2005 |
I am in my 60s and have been taking Fosamax for osteoporosis. I was recently diagnosed with osteo arthritis in my knees. Since Fosamax helps bones, could it do something for the bones in my knees?
Topics: Alendronate; Female; Humans; Middle Aged; Osteoarthritis, Knee; Osteoporosis | 2005 |